The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer

Conclusions: Although the elevation of PSA and hemoglobin may lead to the progression of bone marrow lesions during Ra-223-dichloride treatment, elevations of SUVs, ALP, and BAP suggest that areas with a high osteoblastic activity had a high-absorbed dose of alpha radiation and suppressed osteoblastic activity. The amount of bone metastatic lesions demonstrated by BSI, MBV, or TBU did not significantly change, and 1-CTP of osteolytic bone metastases had increased during the treatment. Therefore, the Ra-223-dichloride therapy was considered to have little inhibitory effect on osteolytic metastases and a therapeutic effect mainly on osteoblastic bone metastatic lesions, leading to little effect on the burden of bone metastatic lesions. These results suggest that bone SUVmax may be more useful than BSI in evaluating the efficacy of Ra-233-dichloride therapy.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: GU - Radioligand Therapy (Poster Session) Source Type: research